University Hospital Schleswig-Holstein in Kiel, Germany selects DigniCap
Dignitana AB announces that the highly ranked University Hospital Schleswig-Holstein (UKSH) in Kiel, Germany will offer DigniCap for patients at the Clinic for Gynecology and Obstetrics.
The clinic acquired two DigniCap Delta devices and the staff completed the training in October. UKSH chose DigniCap based on the advanced technology in the DigniCap Delta device which is designed to improve patient outcomes and ease of use.
“UKSH offers patients comprehensive cancer care with the most advanced diagnostics and treatments. The quality-of-life benefits of DigniCap align well with our integrative approach to cancer care, and we have already seen strong patient demand for DigniCap,” said PD Dr.med. Mohamed Elessawy, M.D., Clinic for Gynecology and Obstetrics University Hospital Schleswig-Holstein, Kiel Campus who has led the introduction of DigniCap to the medical center.
“UKSH is a prominent leader in cancer care are we are excited to make DigniCap available to UKSH patients providing access to the next generation technology found only in DigniCap Delta,” said Fredrik Jonsson, Dignitana CEO.
The University Medical Center Schleswig-Holstein (UKSH) is a top medical institution in northern Germany, offering specialized, high-quality cancer care. Recognized and funded by German Cancer Aid as an Oncology Center of Excellence, UKSH is one of Europe’s most advanced medical centers.
For More Information Contact
Fredrik Jonsson, CEO, fredrik.jonsson@dignitana.com +46 708766444
About Dignitana
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.